Raseglurant
   HOME

TheInfoList



OR:

Raseglurant ( INN) (code name ADX-10059) is a negative allosteric modulator of the mGlu5 receptor and
derivative In mathematics, the derivative of a function of a real variable measures the sensitivity to change of the function value (output value) with respect to a change in its argument (input value). Derivatives are a fundamental tool of calculus. ...
of MPEP which was under development by Addex Therapeutics for the treatment of
migraine Migraine (, ) is a common neurological disorder characterized by recurrent headaches. Typically, the associated headache affects one side of the head, is pulsating in nature, may be moderate to severe in intensity, and could last from a few hou ...
,
gastroesophageal reflux disease Gastroesophageal reflux disease (GERD) or gastro-oesophageal reflux disease (GORD) is one of the upper gastrointestinal chronic diseases where stomach content persistently and regularly flows up into the esophagus, resulting in symptoms and/ ...
, and
dental anxiety Dental fear, or dentophobia, is a normal emotional reaction to one or more specific threatening stimuli in the dental situation. However, dental anxiety is indicative of a state of apprehension that something dreadful is going to happen in relatio ...
. It reached phase II
clinical trial Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, diet ...
s for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of
hepatotoxicity Hepatotoxicity (from ''hepatic toxicity'') implies chemical-driven liver damage. Drug-induced liver injury is a cause of acute and chronic liver disease caused specifically by medications and the most common reason for a drug to be withdrawn fr ...
in patients with long-term use.


See also

* Basimglurant *
Dipraglurant Dipraglurant ( INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). As of 2014, it i ...
* Fenobam * Mavoglurant


References


External links


Development of ADX10059 Ended for Long-term Use - Addex Therapeutics
MGlu5 receptor antagonists Fluoroarenes Aminopyridines Alkyne derivatives {{nervous-system-drug-stub